Advertisement

Evaluation of treatment with doxorubicin and piroxicam or doxorubicin alone for multicentric lymphoma in dogs

Anthony J. MutsaersDepartment of Veterinary Clinical Sciences, School of Veterinary Medicine, Purdue University, West Lafayette, IN 47907.

Search for other papers by Anthony J. Mutsaers in
Current site
Google Scholar
PubMed
Close
 DVM
,
Nita W. GlickmanDepartment of Office of Research Programs, School of Veterinary Medicine, Purdue University, West Lafayette, IN 47907.

Search for other papers by Nita W. Glickman in
Current site
Google Scholar
PubMed
Close
 MS, MPH
,
Dennis B. DeNicolaDepartment of Veterinary Pathobiology, School of Veterinary Medicine, Purdue University, West Lafayette, IN 47907.

Search for other papers by Dennis B. DeNicola in
Current site
Google Scholar
PubMed
Close
 DVM, PhD, DACVP
,
William R. WidmerDepartment of Veterinary Clinical Sciences, School of Veterinary Medicine, Purdue University, West Lafayette, IN 47907.

Search for other papers by William R. Widmer in
Current site
Google Scholar
PubMed
Close
 DVM, DACVR
,
Patty L. BonneyDepartment of Veterinary Clinical Sciences, School of Veterinary Medicine, Purdue University, West Lafayette, IN 47907.

Search for other papers by Patty L. Bonney in
Current site
Google Scholar
PubMed
Close
 BS
,
Kevin A. HahnDepartment of Veterinary Clinical Sciences, School of Veterinary Medicine, Purdue University, West Lafayette, IN 47907.
Present address is Gulf Coast Veterinary Oncology, 1111 Loop S, Ste 150, Houston, TX 77027.

Search for other papers by Kevin A. Hahn in
Current site
Google Scholar
PubMed
Close
 DVM, PhD, DACVIM
, and
Deborah W. KnappDepartment of Veterinary Clinical Sciences, School of Veterinary Medicine, Purdue University, West Lafayette, IN 47907.

Search for other papers by Deborah W. Knapp in
Current site
Google Scholar
PubMed
Close
 DVM, MS, DACVIM

Abstract

Objective—To evaluate the antitumor and toxic effects of treatment with doxorubicin combined with piroxicam or doxorubicin alone for multicentric lymphoma in dogs.

Design—Nonrandomized clinical trial.

Animals—75 dogs with multicentric lymphoma.

Procedure—33 dogs were treated with doxorubicin (30 mg/m2, IV, q 21 d, for 3 doses) and piroxicam (0.3 mg/kg [0.14 mg/lb], PO, q 24 h); results were compared with a historical control group of 42 dogs treated with doxorubicin (30 mg/m2, IV, q 21 d, for 3 doses) alone.

Results—The percentages of dogs that had remission with doxorubicin-piroxicam treatment (79%) or doxorubicin treatment alone (74%) were not significantly different. Median duration of first remission was 130 days with doxorubicin-piroxicam and 147 days with doxorubicin alone; these values were not significantly different. Severe toxicosis was observed in 22% of dogs treated with doxorubicin-piroxicam and 17% of dogs treated with doxorubicin alone.

Conclusions and Clinical Relevance—Both treatment protocols were efficacious and well tolerated. The doxorubicin-piroxicam treatment was no more effective regarding response rate, remission duration, or survival duration, compared with the control group treated with doxorubicin alone. (J Am Vet Med Assoc 2002;220:1813–1817)

Abstract

Objective—To evaluate the antitumor and toxic effects of treatment with doxorubicin combined with piroxicam or doxorubicin alone for multicentric lymphoma in dogs.

Design—Nonrandomized clinical trial.

Animals—75 dogs with multicentric lymphoma.

Procedure—33 dogs were treated with doxorubicin (30 mg/m2, IV, q 21 d, for 3 doses) and piroxicam (0.3 mg/kg [0.14 mg/lb], PO, q 24 h); results were compared with a historical control group of 42 dogs treated with doxorubicin (30 mg/m2, IV, q 21 d, for 3 doses) alone.

Results—The percentages of dogs that had remission with doxorubicin-piroxicam treatment (79%) or doxorubicin treatment alone (74%) were not significantly different. Median duration of first remission was 130 days with doxorubicin-piroxicam and 147 days with doxorubicin alone; these values were not significantly different. Severe toxicosis was observed in 22% of dogs treated with doxorubicin-piroxicam and 17% of dogs treated with doxorubicin alone.

Conclusions and Clinical Relevance—Both treatment protocols were efficacious and well tolerated. The doxorubicin-piroxicam treatment was no more effective regarding response rate, remission duration, or survival duration, compared with the control group treated with doxorubicin alone. (J Am Vet Med Assoc 2002;220:1813–1817)